Cannara Biotech Inc.

OTCPK:LOVF.F Stock Report

Market Cap: US$46.1m

Cannara Biotech Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:LOVF.F Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
12 Dec 24BuyUS$5,357Nicholas SosiakIndividual10,704US$0.50
10 Dec 24BuyUS$13,698Donald OldsIndividual25,000US$0.55
29 Nov 24BuyUS$21,508Investissements Olymbec Inc.Company40,000US$0.55
28 Nov 24BuyUS$8,030Nicholas SosiakIndividual15,000US$0.54
21 Aug 24BuyUS$67,751Investissements Olymbec Inc.Company120,500US$0.56
15 Aug 24BuyUS$31,893Investissements Olymbec Inc.Company63,500US$0.50
14 Aug 24BuyUS$11,270Donald OldsIndividual25,065US$0.45
26 Jul 24BuyUS$1,697Nicholas SosiakIndividual3,916US$0.43
26 Jul 24BuyUS$21,699Investissements Olymbec Inc.Company48,000US$0.45
21 May 24BuyUS$3,605Investissements Olymbec Inc.Company6,000US$0.60
17 May 24BuyUS$6,031Investissements Olymbec Inc.Company10,000US$0.60
16 May 24BuyUS$12,792Investissements Olymbec Inc.Company22,000US$0.59
13 May 24BuyUS$3,501Investissements Olymbec Inc.Company6,000US$0.58
10 May 24BuyUS$15,212Investissements Olymbec Inc.Company27,000US$0.57
10 May 24BuyUS$2,383Anthony ManoukIndividual4,400US$0.54
09 May 24BuyUS$16,990Donald OldsIndividual30,000US$0.57
08 May 24BuyUS$6,593Investissements Olymbec Inc.Company12,000US$0.55
07 May 24BuyUS$1,664Nicholas SosiakIndividual3,000US$0.55
29 Feb 24BuyUS$72,129Investissements Olymbec Inc.Company100,000US$0.74

Insider Trading Volume

Insider Buying: LOVF.F insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of LOVF.F?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,891,8302.1%
General Public43,938,38348.8%
Private Companies44,188,73949.1%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 8 shareholders own 51.19% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
27%
Javaa Private Equity Inc.
24,258,982US$12.4m0%no data
22.1%
Investissements Olymbec Inc.
19,929,757US$10.2m0%no data
1.37%
Donald Olds
1,235,685US$633.0k2.06%no data
0.42%
Derek Stern
376,040US$192.6k0%no data
0.24%
Jacob Kay
219,000US$112.2k0%no data
0.06%
Nicholas Sosiak
53,600US$27.5k92.1%no data
0.0049%
Anthony Manouk
4,400US$2.3k0%no data
0.0034%
Scott Carroll
3,105US$1.6k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 09:09
End of Day Share Price 2025/01/02 00:00
Earnings2024/08/31
Annual Earnings2024/08/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cannara Biotech Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution